- If you are wondering whether Organon is simply beaten down or genuinely cheap, this article will walk through what the current share price might be implying about the company.
- The stock last closed at US$6.35, with returns of a 3.2% decline over 7 days, a 17.4% decline over 30 days, a 12.3% decline year to date and a 58.1% decline over the past year. This naturally raises questions about how the market is thinking about its risk and potential.
- Recent coverage around Organon has focused on its position as a standalone women's health and biosimilars business and how it is managing its portfolio after separation from its former parent company. This context is important when thinking about why the share price sits where it does and what investors may be expecting from its product mix and capital allocation.
- Our valuation model gives Organon a value score of 5 out of 6. We will break this down using different valuation approaches before finishing with a simple way to keep track of the story behind that score over time.
Find out why Organon's -58.1% return over the last year is lagging behind its peers.
Approach 1: Organon Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those cash flows back to a present value.
For Organon, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in US$. The latest twelve month free cash flow is about $394.5 million. Analysts provide specific forecasts for the next few years, and then Simply Wall St extends those projections further out. By 2030, free cash flow is projected at $1.346b, with discounted values provided for each year from 2026 through 2035.
When all of those discounted cash flows are added together, the model arrives at an estimated intrinsic value of about $59.99 per share. Compared with the recent share price of US$6.35, this implies an intrinsic discount of 89.4%, which suggests the stock screens as heavily undervalued on this DCF view.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Organon is undervalued by 89.4%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.
Approach 2: Organon Price vs Earnings
For companies that are generating profits, the P/E ratio is a straightforward way to see how much investors are currently paying for each dollar of earnings. It connects directly to what matters most for shareholders, the earnings that support dividends, buybacks and reinvestment.
What counts as a "normal" P/E ratio often reflects how the market views a company’s growth potential and risk. Higher expected growth and lower perceived risk can support a higher P/E, while slower growth or higher risk usually go with a lower P/E.
Organon is trading on a P/E of 8.84x. That sits below the Pharmaceuticals industry average of 17.42x and also below the peer group average of 12.39x. Simply Wall St’s Fair Ratio for Organon is 23.99x, which is its proprietary view of what the P/E could be based on factors like earnings growth, profit margins, industry, market cap and specific risks.
The Fair Ratio aims to be more tailored than a simple comparison to peers or the broad industry because it adjusts for Organon’s own characteristics rather than assuming all companies should trade on the same multiple. Set against the current 8.84x, the Fair Ratio of 23.99x suggests the shares screen as undervalued on this P/E view.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your Organon Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce Narratives, a simple tool on Simply Wall St’s Community page that lets you attach your own story about Organon to the numbers. It connects your view on its future revenue, earnings and margins to a forecast, a Fair Value and then a clear comparison with today’s price. All of this then updates automatically when new earnings, guidance or news arrives. You can see, for example, how one investor might build a bullish Organon Narrative around a Fair Value of US$18.00, while another builds a far more cautious one around US$5.00, and use those different Fair Values against the current market price to help decide whether they see Organon as closer to a buy, a hold, or a sell.
For Organon, however, we will make it really easy for you with previews of two leading Organon Narratives:
Each one takes the same company data and arrives at a very different conclusion about what the shares are worth. Your job is not to pick a winner on the spot, but to see which set of assumptions feels closer to how you see Organon’s future.
Fair value: US$9.00
Implied discount to this fair value vs last close: 29.4%
Revenue growth assumption: 71.06%
- Analysts in this camp focus on new product launches, biosimilars adoption and portfolio mix shifts that support revenue growth and margin improvement over time.
- They point to debt reduction and free cash flow as giving Organon more room to invest, pursue M&A and support longer term earnings.
- They still flag risks around legacy products, policy and pricing pressure, and reliance on external deals, but see these as manageable within their earnings and P/E assumptions.
Fair value: US$5.00
Implied overvaluation vs this fair value at last close: 27.0%
Revenue growth assumption: 1.85% decline
- This group puts more weight on internal control issues, Nexplanon related channel stuffing concerns and softer guidance, and therefore applies a higher risk premium.
- They expect modest revenue contraction, a much lower future P/E multiple and a tighter view on how much debt, governance and regulatory scrutiny could weigh on earnings quality.
- They acknowledge progress in areas like biosimilars and operational efficiencies, but treat these as insufficient to offset the pressure they see from pricing, patent cliffs and policy headwinds.
The key takeaway for you is that both narratives use reasonable building blocks, yet arrive at very different fair values. If you want to see these stories in full and stress test your own view against them, Curious how numbers become stories that shape markets? Explore Community Narratives.
Do you think there's more to the story for Organon? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com